Neil Palmer - Health & BioPharma Policy

Pricing, reimbursement, market access & Canadian health and pharma policy.

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

@FedCourtApp_en quashes #PMPRB Alexion decision as unreasoned, unreasonable, and beyond its mandate. Ramifications extend well beyond this case to the appropriateness, legality and constitutionality of PMPRB’s new Guidelines. https://t.co/FtKUx5FC17

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

#PMPRB “appropriate response” for delayed Regulations is significantly more punitive price guideline for on-market drugs. No rationale, no supporting analyses, no #HESA oversight possible in dog-days of summer prior to election. Consultation closes Aug15. https://t.co/HQKXJFfdBu

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

Prelim analysis suggests draft @PMPRB_CEPMB Guidelines to cost pharma manufacturers ~$3.5B annually beginning 2021. Greater impact in future years as list prices for new medicines approach lowest international price and some rebated net prices forced even lower. @PDCImktaccess

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

September 4 @ 2pm. Register now! PDCI hosting an industry-only webinar with all the latest on the amended PMPRB Regulations, implications and the process going forward.

[PDCI Market Access @PDCImktaccess]

WEBINAR: PDCI senior staff and partners will be hosting a webinar on September 4th, 2019 at 2 p.m. for an industry-only #webinar to discuss the final amendments to the Patented Medicines Regulation.

Registration Link: https://t.co/D6zVBISCHT

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

It's not just Canada's pharma industry - no one in Canada want's this - no benefits - just threats of higher prices, drug shortages and delayed access to innovative new drugs.

[Robert King @rking_19]

In another warning sign for HHS' drug import plan, Canada's pharma industry wants the country to act early to on any plan before a shortage could arise, according to Reuters https://t.co/3vmpnrzQIM

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

@NASHPhealth Why would Canada play ball? No upside for Canada - only potential for higher prices, drug shortages and no new innovative drugs if there is any risk they will cross border.

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

@GinettePT @HHSGov A firm, unequivocal "No!" is required from Canadian gov't - no benefit to Canada, only threats: higher prices, drug shortages but most importantly: innovative new drugs will not come to Canada if there is any risk of @HHSGov #ImportfromCanada

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

@lurvejennifer @Easterngirl77 @lastchance4usa @JimmyTheRip @SecAzar And drug makers will seek to remove price differentials between the countries by raising prices in Canada (if they can) or by not selling the drug in Canada at all. There is no upside to Canada, just threats to the drug supply and increased drug costs.

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

@lurvejennifer @Easterngirl77 @lastchance4usa @JimmyTheRip @SecAzar Many drugs sold in Canada are manufactured in the US and then sent to Canada in sufficient quantities to supply the Canadian market (10% of US). If they are sent back to the US there would be shortages in Canada (but not enough to supply the US in a meaningful way).

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

@SecAzar And ironic that the press release touts the potential to import lower cost #insulin which as biologic products would not be eligible for importation (as laid out in the action plan) https://t.co/tEe8IVZv8h

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

@SecAzar Proposed US prescription drug #importation action plan is both impractical and very bad for #Canada: threat of higher drug prices, drug shortages and delayed (or no) access to important new drugs for Canadians. https://t.co/gvYqi5sY4P

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

Thank you to everyone wearing plaid today #PlaidforDad and supporting @ProstateCancerC. If detected early, survival is close to 100%; but too many men are still diagnosed late, risking advanced, metastatic disease and death - so 50+ men, please see your doctor & get tested.

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

Proud to have participated in the @ProstateCancerC grant review panel for accelerated translation of predictive markers. $4M in research funding to support Canadian scientists improve diagnosis and treatment of #ProstateCancer!

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

@inhilley

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

Thank you CORD @raredisorders for inviting me to present on National #Pharmacare - a great discussion - all Canadians should have comprehensive prescription drug coverage & timely access to drugs for #rarediseases https://t.co/JhNRurQMf7

[CORD @raredisorders]

Thank you @survivornetca for the webcast of the Bringing Rare Disease Drugs to Canada Panel. Informative discussion @SherryOQuinn @Durhane @PDCINeil @JohnOliverMP Moderator @billdempster @3SixtyPA #Canada4Rare

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

PMPRB price control regime was never tied to R&D expenditures – yet that myth is the rationale for proposed punitive price regulations & guidelines. Setting the record straight: https://t.co/UYfpyQoZse #PMPRB #CdnHealth

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

Proposed @PMPRB_CEPMB Regs/RIAS willfully ignore 2016 pricing data available to #PMPRB since Feb 2017. Failure to acknowledge potential impact limiting patient access to new meds. Blog with more reaction/analysis coming soon to https://t.co/iakcbfZpMU
https://t.co/uM1ftw26zN

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

Its "Right to Know" week! https://t.co/iSFa0HzTLT Good time to release long delayed #PMPRB 2016 Annual Report! @CDNMinHealth @PMPRB_CEPMB

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

@NavPersaud Agreed. But how many others looking at impersonating website? Proper website & contact info should have been on Ltr to Minister.

[Neil Palmer - Health & BioPharma Policy @Neil_HlthPolicy]

@NavPersaud Blog text based solely on official OpenPharma letter to Minister. Only italic postscript looked at impersonating openpharma.ca website.